Recently, encryption Tokens in the biopharmaceutical field have attracted widespread follow. However, after in-depth analysis, it is found that Tokens such as BIO, NBIO, and VITA do not actually capture any substantial value. Investors who purchase these Tokens often find that their actual utility is extremely limited.

In fact, the development of innovative drugs is a long and arduous process. A new drug typically takes up to 10 years from concept to market, requiring a huge investment of human, material, and financial resources. Even more challenging is the extremely low success rate of new drug development, which can be described as a life-or-death situation. In such a high-risk context, it is difficult to attract enough funding to support this process if potential high returns cannot be provided to investors.

It is worth noting that genuinely commercially valuable biopharmaceutical R&D projects usually do not choose to raise funds through the encryption currency market. The traditional stock market has been able to provide ample financial support for these projects. In contrast, many projects in the encryption currency market seem to focus more on quickly raising funds rather than on real scientific research value.

Some biopharmaceutical-related Token projects have publicly stated that their main goal is to raise funds to support scientific development. This statement essentially means that they plan to sell all Tokens to retail investors in order to raise research funds. For those retail investors who hope to profit from speculation on Tokens, this may mean that they will bear most of the risk, while the project parties receive funding support.

This model has raised concerns about risk allocation. Compared to major shareholders in traditional stock markets, these encryption token projects seem more inclined to shift the risks onto retail investors. Therefore, investors need to be particularly cautious and comprehensively assess the potential risks and returns when considering participation in such projects.